SphingoTec GmbH has received its IVDR certificate for its sphingotest® penKid® confirming the quality and compliance of this product with regulatory requirements.Sphingotest® penKid® aids in the diagnosis
Renal Biomarker Market is anticipated to experience a 7.0% year-over-year growth in demand, reaching US$ 2.6 billion in 2032.According to Future Market Insights analysts, a rising prevalence of renal diseases is likely to boost the growth of the global renal biomarker market over the forecast period. Other prominent.
Issuer: SphingoTec GmbH / Key word(s): Research Update/Study results ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury 04.04.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. The Acute Disease Qualit.